Research Topics
Species | William T AbrahamSummaryAffiliation: The Ohio State University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremiaWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio 43210 1252, USA
Kidney Int 82:1223-30. 2012..After drug discontinuation, serum sodium concentrations decreased to near-baseline levels within 7 days. Thus, lixivaptan safely and effectively corrects serum sodium concentrations in patients with euvolemic hyponatremia...- Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremiaWilliam T Abraham
Division of Cardiovascular Medicine, Ohio State University, Columbus, Ohio 43210 1252, USA
Kidney Int 82:1215-22. 2012..2%). Overall, lixivaptan was considered safe and well-tolerated. Thus, oral lixivaptan can be safely initiated in the outpatient setting and effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia... - Devices in the management of advanced, chronic heart failureWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University, 473 West 12th Avenue, Room 110P, Columbus, OH 43210 1252, USA
Nat Rev Cardiol 10:98-110. 2013.... - Randomized controlled trial comparing simultaneous versus optimized sequential interventricular stimulation during cardiac resynchronization therapyWilliam T Abraham
The Ohio State University Heart Center, Columbus, OH Electronic address
Am Heart J 164:735-41. 2012..This randomized, double-blind, controlled study evaluated whether optimizing the interventricular stimulating interval (V-V) to sequentially activate the ventricles is clinically better than simultaneous V-V stimulation during CRT... - Randomized controlled trial of ventricular elastic support therapy in the treatment of symptomatic heart failure: Rationale and designWilliam T Abraham
The Ohio State University Heart Center, Columbus, OH Electronic address
Am Heart J 164:638-45. 2012..The Prospective Evaluation of Elastic Restraint to LESSen the effects of Heart Failure (PEERLESS-HF) trial was designed to further evaluate the safety and efficacy of one such device, the HeartNet (Paracor Medical, Sunnyvale, CA)... 
Intrathoracic impedance monitoring for early detection of impending heart failure decompensationWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University College of Medicine and Public Health, Columbus, OH 43210, USA
Congest Heart Fail 13:113-5. 2007..This review discusses the basic concepts underlying intrathoracic impedance monitoring, the clinical evidence supporting its use, and some common pitfalls to avoid when interpreting intrathoracic impedance data...- Subgroup analysis of a randomized controlled trial evaluating the safety and efficacy of cardiac contractility modulation in advanced heart failureWilliam T Abraham
Ohio State University Heart Center, Columbus, Ohio, USA
J Card Fail 17:710-7. 2011..In the present analysis, we sought to identify if there was a subgroup of patients who showed a response to CCM... - Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST)William T Abraham
Division of Cardiovascular Medicine, Ohio State University, 473 West 12th Avenue, Columbus, OH 43210 1252, USA
Congest Heart Fail 17:51-5. 2011..Intrathoracic impedance monitoring represents a useful adjunctive clinical tool for managing HF in patients with implanted devices... - Treatment of anemia with darbepoetin alfa in heart failureWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University Medical Center, Davis Heart and Lung Research Institute, Columbus, OH 43210, USA
Congest Heart Fail 16:87-95. 2010..These results suggest that DA is well tolerated, corrects HF-associated anemia, and may have favorable effects on clinical outcomes... - A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: rationale, design, and baseline patient characteristicsWilliam T Abraham
The Ohio State University Heart Center, Division of Cardiovascular Medicine, Columbus, OH 43210 1252, USA
Am Heart J 156:641-648.e1. 2008..Baseline characteristics for patients randomized in this trial are also presented... - Validation and clinical utility of a simple in-home testing tool for sleep-disordered breathing and arrhythmias in heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Congestive Heart Failure (SEARCH) studyWilliam T Abraham
The Ohio State University Heart Center, Davis Heart and Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210 1252, USA
Congest Heart Fail 12:241-7; quiz 248-9. 2006..The device was judged by 80% of patients to be easy or very easy to use, and 74% of patients expressed a preference for the in-home system. Therefore, this system represents a reasonable home testing device in these patients... - Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: the Frequent Optimization Study Using the QuickOpt Method (FREEDOM) trialWilliam T Abraham
The Ohio State University, Columbus, OH 43017, USA
Am Heart J 159:944-948.e1. 2010.... - Safety and accuracy of a wireless pulmonary artery pressure monitoring system in patients with heart failureWilliam T Abraham
The Ohio State University Heart Center, Columbus, USA
Am Heart J 161:558-66. 2011..The goal of this investigation was to evaluate the safety and technical performance of a novel wireless pulmonary artery pressure monitoring system in 17 patients with symptomatic HF... - Cardiac resynchronization therapy is important for all patients with congestive heart failure and ventricular dyssynchronyWilliam T Abraham
Department Internal Medicine, Division of Cardiovascular Medicine, and The Davis Heart and Lung Research Institute, Ohio State University, Columbus, USA
Circulation 114:2692-8; discussion 2698. 2006 - Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) studyWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University Heart Center, Columbus, USA
Clin Transl Sci 3:249-53. 2010..BALANCE seeks to address unmet questions regarding the use of vasopressin antagonists including their effects on cognitive function and clinical outcomes in patients with hyponatremia and worsening heart failure... - Pharmacologic therapies across the continuum of left ventricular dysfunctionWilliam T Abraham
Division of Cardiovascular Medicine, Ohio State University Medical Center, Columbus, Ohio 43210, USA
Am J Cardiol 102:21G-28G. 2008..This review illustrates the impact of these therapies on post-MI LVD patients using evidence from multiple clinical trials. In addition, current and emerging treatments for acute decompensated HF will be outlined... - Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trialsWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
Clin Cardiol 33:484-9. 2010..This study used relevant data from all RCTs of nesiritide in ADHF completed as of June 2006 to independently estimate the effect of nesiritide on 30- and 180-day mortality... - Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)William T Abraham
Division of Cardiology, The Ohio State University, Columbus, Ohio, USA
J Am Coll Cardiol 52:347-56. 2008..The aim of this study was to develop a clinical model predictive of in-hospital mortality in a broad hospitalized heart failure (HF) patient population... - Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failureMihai Gheorghiade
Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill, USA
JAMA 296:2217-26. 2006..These findings may have important therapeutic implications because characteristics and outcomes differ greatly among patients with heart failure with varying SBP... - Beta-blocker dosing in community-based treatment of heart failureMichael B Fowler
Division of Cardiovascular Medicine, Stanford University Medical Center, Palo Alto, CA, USA
Am Heart J 153:1029-36. 2007..Community patients with heart failure (HF) are older, less often treated by HF specialists, and have more comorbidity than those in randomized clinical trials. These differences might affect beta-blocker prescribing in HF... - Cardiac resynchronization therapy for the management of chronic heart failureWilliam T Abraham
Department of Internal Medicine, Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA
Am Heart Hosp J 1:55-61. 2003..Thus, cardiac resynchronization therapy should be routinely considered in eligible NYHA class III and IV heart failure patients with ventricular dyssynchrony... - Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failureMartin G St John Sutton
Division of Cardiology, University of Pennsylvania Medical Center, Philadelphia, 19104, USA
Circulation 107:1985-90. 2003..The purpose of the present study was to determine whether improvements in left ventricular (LV) size and function were associated with CRT... - Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registryMihai Gheorghiade
Division of Cardiology, Feinberg School of Medicine, Northwestern University, Galter 10 240, 201 E Huron Street, Chicago, IL 60611, USA
Eur Heart J 28:980-8. 2007..The predictive value of hyponatraemia has not been evaluated in unselected patients hospitalized with heart failure... - Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry)James B Young
Department of Cardiovascular Medicine, Heart Failure Section, Cleveland Clinic Foundation, Cleveland, Ohio, USA
Am J Cardiol 101:223-30. 2008..Lower hemoglobin is associated with higher morbidity and mortality in hospitalized patients with HF... - Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failureWilliam T Abraham
Ohio State University Heart Center, Division of Cardiovascular Medicine, 473 W 12th Ave, Room 110P DHLRI, Columbus, OH 43210 1252
Circulation 110:2864-8. 2004..The effects of cardiac resynchronization therapy (CRT) in patients with mildly symptomatic heart failure have not been fully elucidated... - Application of implantable hemodynamic monitoring in the management of patients with diastolic heart failure: a subgroup analysis of the COMPASS-HF trialMichael R Zile
Division of Cardiology, Departmentof Medicine, Medical University of South Carolina and RHJ Department of Veterans Affairs Medical Center, Charleston, SC 29425, USA
J Card Fail 14:816-23. 2008..However, appropriate management of DHF patients remains a difficult and uncertain challenge... - In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)William T Abraham
Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
J Am Coll Cardiol 46:57-64. 2005..We sought to compare the in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving parenteral treatment with one of four intravenous vasoactive medications... - Heart failure with normal ejection fraction: consideration of mechanisms other than diastolic dysfunctionTravis Bench
Division of Cardiology, Columbia University, 177 Fort Washington Avenue, New York, NY 10032, USA
Curr Heart Fail Rep 6:57-64. 2009..In this article, we review the current understanding of nondiastolic mechanisms that may contribute to the HF with normal EF syndrome to highlight potential pathways for research that may lead to new targets for therapy... - Hemodynamic factors associated with acute decompensated heart failure: part 1--insights into pathophysiologyMichael R Zile
Division of Cardiology, Medical University of South Carolina, 25 Courtenay Drive, Charleston, SC 29425, USA
J Card Fail 17:282-91. 2011..The purpose of this study was to determine which pressure-based hemodynamic factor was most closely associated with the transition from chronic compensated to acute decompensated heart failure... - Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trialWilliam T Abraham
Ohio State University Heart and Vascular Center, Columbus, OH, USA
Lancet 377:658-66. 2011..Results of previous studies support the hypothesis that implantable haemodynamic monitoring systems might reduce rates of hospitalisation in patients with heart failure. We undertook a single-blind trial to assess this approach... - Congestion is an important diagnostic and therapeutic target in heart failureMihai Gheorghiade
Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
Rev Cardiovasc Med 7:S12-24. 2006..Identification of hemodynamic congestion, before the clinical manifestations appear, may potentially prevent hospitalization and slow the progression of HF by allowing life-saving interventions to be implemented sooner... - Percutaneous left ventricular partitioning in patients with chronic heart failure and a prior anterior myocardial infarction: Results of the PercutAneous Ventricular RestorAtion in Chronic Heart failUre PaTiEnts TrialErnest L Mazzaferri
Division of Cardiovascular Medicine, The Ohio State University Heart and Vascular Center, 473 West 12th Ave, Columbus, OH 43210 1252, USA
Am Heart J 163:812-820.e1. 2012..The aim of this study was to assess the feasibility, safety, and preliminary efficacy of a novel percutaneous left ventricular partitioning device (VPD) in patients with chronic heart failure (HF) and a prior anterior myocardial infarction... - Cardiac resynchronization therapyWilliam T Abraham
Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210 1252, USA
Prog Cardiovasc Dis 48:232-8. 2006..Cardiac resynchronization therapy has been shown to significantly improve LV structure and function, New York Heart Association functional class, exercise tolerance, quality of life, and morbidity and mortality... - Canine nonischemic left ventricular dysfunction: a model of chronic human cardiomyopathyYoshinori Nishijima
Department of Veterinary Biosciences, The Ohio State University, Columbus, Ohio 43210, USA
J Card Fail 11:638-44. 2005.... - Effect of treatment with continuous positive airway pressure or oxygen on sleep-disordered breathing in patients with heart failure: results of the Sleep Events, Arrhythmias, and Respiratory Analysis in Chronic Heart Failure (SEARCH) studyWilliam T Abraham
The Ohio State University Heart Center, Columbus, OH 43210, USA
Congest Heart Fail 14:197-201. 2008..5%) experienced a 16.7-events/h mean reduction in AHI. Thus, the Clear Path system appears to be a useful device to monitor response to SDB-directed treatment for apnea in patients with heart failure... 
Cardiac effects of continuous and bilevel positive airway pressure for patients with heart failure and obstructive sleep apnea: a pilot studyRami N Khayat
Sleep Heart Program, Ohio State University, Columbus, OH 43210, USA
Chest 134:1162-8. 2008..The intermediate-term effect of bilevel PAP on left ventricular ejection fraction (LVEF) in patients with stable heart failure and OSA has not been compared to the effect of CPAP...- Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) studyMichael R Gold
Division of Cardiology, Medical University of South Carolina, 25 Courtenay Dr, ART 7031, Charleston, SC 29425 5920, USA
Circulation 126:822-9. 2012..We aimed to assess the impact of baseline QRS duration and morphology and the change in QRS duration with pacing on CRT outcomes in mild heart failure... - Reproducibility of peak oxygen uptake and other cardiopulmonary exercise parameters: implications for clinical trials and clinical practiceSteven J Keteyian
Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, MI 48202, USA
Chest 138:950-5. 2010.... - Predictors of remodeling in the CRT era: influence of mitral regurgitation, BNP, and genderThomas P Cappola
Division of Cardiovascular Medicine, University of Pennsylvania School of Medicine, Philadelphia, USA
J Card Fail 12:182-8. 2006..Future studies should take these clinical factors into account when determining the influence of genetic factors and novel therapies on ventricular remodeling in chronic heart failure... - Optimization of cardiac resynchronization devices using acoustic cardiography: a comparison to echocardiographyAyesha Hasan
Division of Cardiology, The Ohio State University, Columbus, OH 43210, USA
Congest Heart Fail 12:25-31. 2006..7%). In addition, it took less time for the acoustic cardiogram to collect sufficient information to make a recommendation, and it was found that the acoustic cardiogram data trend is easier to interpret... - Beyond diuretics: management of volume overload in acute heart failure syndromesJames A Hill
Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA
Am J Med 119:S37-44. 2006.... - Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressuresMichael R Zile
Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, SC 29425, USA
Circulation 118:1433-41. 2008..The purpose of this study was to use echocardiographic and implantable hemodynamic monitor data to examine the pathophysiology of chronic compensated and acute decompensated HF in SHF versus DHF patients... - Effect of cardiac resynchronization therapy on myocardial gene expression in patients with nonischemic dilated cardiomyopathySrinivas Iyengar
Division of Cardiovascular Medicine and the Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210 1252, USA
J Card Fail 13:304-11. 2007.... - Noninvasive calibration of cardiac pressure transducers in patients with heart failure: an aid to implantable hemodynamic monitoring and therapeutic guidanceDougal McClean
Division of Cardiology, Department of Medicine, and the Research Institute at Cedars-Sinai Medical Center, Los Angeles, California, USA
J Card Fail 12:568-76. 2006.... - Cardiac resynchronization therapy for heart failure: biventricular pacing and beyondWilliam T Abraham
Division of Cardiovascular Medicine, Gill Heart Institute, Heart Failure and Cardiac Transplantation Program, University of Kentucky College of Medicine, Lexington, Kentucky 49536, USA
Curr Opin Cardiol 17:346-52. 2002..In addition, the results of recently completed clinical trials, as well as the status of ongoing clinical trials, are reviewed... - Biventricular and novel pacing mechanisms in heart failureChristina Salazar
Ohio State University, 473 West 12th Avenue, Columbus, OH 43210, USA
Curr Heart Fail Rep 6:14-8. 2009..In this article, we review CRT's effects on reverse remodeling in an expanding patient population and as a novel pacing mechanism, its cardiac contractility modulation, and its benefits in patients with heart failure... - Cardiac resynchronization in chronic heart failureWilliam T Abraham
Division of Cardiovascular Medicine, University of Kentucky College of Medicine, Lexington 40536 0284, USA
N Engl J Med 346:1845-53. 2002..We conducted a double-blind trial to evaluate this therapeutic approach... - Prevalence of sleep disordered breathing in a heart failure programRobin J Trupp
Davis Heart and Lung Research Institute, Ohio State University, 473 W 12th Avenue, Columbus, OH 43210 1252, USA
Congest Heart Fail 10:217-20. 2004..Forty-two percent of patients with stable heart failure presenting to a heart failure clinic screened positive for SDB, despite receiving optimal standard of care... - Diuretics for the treatment of acute decompensated heart failureSrinivas Iyengar
Division of Cardiovascular Medicine, The Ohio State University, 473 West 12th Avenue, Rm 110P DHLRI, Columbus, Ohio 43210 1252, USA
Heart Fail Rev 12:125-30. 2007..Given this reality and until further information is available about the most ideal utilization of these medications, diuretics will continue to represent a double-edged sword for physicians treating this disease process... - Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockersWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University, Columbus, OH 43210 1252, USA
Congest Heart Fail 11:59-64. 2005..Thus, the clinical and hemodynamic benefits and safety of nesiritide are preserved in decompensated congestive heart failure patients receiving chronic beta blockade... - New approaches to monitoring heart failure before symptoms appearWilliam T Abraham
Division of Cardiovascular Medicine, Department of Internal Medicine, Ohio State University College of Medicine, Columbus, Ohio, USA
Rev Cardiovasc Med 7:S33-41. 2006..IHM systems may extend such monitoring capabilities. Both emerging approaches for monitoring patients with heart failure may alert clinicians (and possibly patients) to impending decompensation before symptoms appear... - In-hospital testing for sleep-disordered breathing in hospitalized patients with decompensated heart failure: report of prevalence and patient characteristicsRami N Khayat
Division of Pulmonary Critical Care and Sleep, Ohio State University, Columbus, OH, USA
J Card Fail 15:739-46. 2009..Sleep-disordered breathing (SDB) is present in more than 50% of ambulatory patients with chronic heart failure. The prevalence and type of SDB in hospitalized patients with acutely decompensated heart failure (ADHF) are not known... - Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidineMyron C Gerson
Division of Cardiology, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA
J Nucl Cardiol 9:608-15. 2002..The goal of this study was to determine the effect of chronic carvedilol treatment in patients with cardiac sympathetic nerve dysfunction of varying severity... - Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and MulticeLuis A Pires
The Heart Rhythm Center, Division of Cardiology, St John Hospital and Medical Center, Detroit, MI 48236, USA
Am Heart J 151:837-43. 2006..The purpose of this analysis is to identify predictors and characterize the timing of response to CRT in patients with advanced heart failure... - Future therapies for heart failureRobin J Trupp
The Heart and Lung Research Institute, The Ohio State University 473 West 12th Avenue, Columbus, OH 43210, USA
Crit Care Nurs Clin North Am 15:525-30, x. 2003..This article discusses recently approved drugs and devices and clinical trials that may affect the management of this challenging disease... - Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failureDavid S Feldman
Davis Heart and Lung Research Institute, Division of Cardiology Medicine, Ohio State University, Columbus, OH 43210, USA
Nat Clin Pract Cardiovasc Med 2:475-83. 2005..In this review, we summarize current insights into beta-adrenergic signal-transduction pathways, the best-described beta-AR polymorphisms, and therapies that target the beta-AR pathway in HF... - Cardiac resynchronization therapy for heart failureWilliam T Abraham
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA
Circulation 108:2596-603. 2003 - Nesiritide for the treatment of congestive heart failureSrinivas Iyengar
Division of Cardiovascular Medicine, The Ohio State University Heart Center, Columbus, OH 43210 1252, USA
Expert Opin Pharmacother 5:901-7. 2004..Overall, nesiritide represents an effective and safe therapeutic option for the treatment of decompensated CHF... - Tolerability, safety, and efficacy of beta-blockade in black patients with heart failure in the community setting: insights from a large prospective beta-blocker registryWilliam T Abraham
Division of Cardiovascular Medicine, The Ohio State University School of Medicine, Columbus, OH, USA
Congest Heart Fail 13:16-21. 2007..9% vs 7.5%, hazard ratio 1.2 vs 1.0, P=.276). Thus carvedilol was similarly effective in blacks and whites with HF in the community setting, consistent with carvedilol clinical trials... - Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)Kirkwood F Adams
Division of Cardiology, University of North Carolina, Chapel Hill, NC, USA
Am Heart J 149:209-16. 2005..Most available data on these patients are limited by patient selection criteria and study design of clinical trials and single-center studies... - Electrophysiological aids in congestive heart failure: supporting and synchronizing systoleWilliam T Abraham
Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH 43210 1252, USA
Med Clin North Am 87:509-21. 2003..Ongoing and future clinical trials should help to further validate the role of cardiac resynchronization in the treatment of patients with systolic HF... - Safety and efficacy of nesiritide for acute decompensated heart failure: recent literature and upcoming trialsBrian Hiestand
Department of Emergency Medicine, The Ohio State University, 149 Means Hall, 1654 Upham Drive, Columbus, OH 43210, USA
Curr Cardiol Rep 9:182-6. 2007..We review the recent evidence regarding the efficacy and safety profile of nesiritide, and discuss upcoming trials designed to address concerns regarding safety and the comparative efficacy of nesiritide... - Practical considerations for switching beta-blockers in heart failure patientsWilliam T Abraham
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University Heart Center, Columbus, Ohio, USA
Rev Cardiovasc Med 5:S36-44. 2004.... - Highlights of Heart Rhythm 2004, the Annual Scientific Sessions of the Heart Rhythm Society: May 19 to 22, 2004, in San Francisco, CaliforniaAnne B Curtis
Division of Cardiovascular Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA
J Am Coll Cardiol 44:1550-6. 2004.... - Implications of heart failure drug trials: COMET, CHARM, EPHESUSBrian Hiestand
Department of Emergency Medicine, Ohio State University, Columbus, Ohio, USA
Rev Cardiovasc Med 6:S4-11. 2005..These trials established that it is feasible to design and execute heart failure studies of sufficient scale to assess improvement in rates of mortality and morbidity... - "Responder analysis" for assessing effectiveness of heart failure therapies based on measures of exercise toleranceDaniel Burkhoff
Division of Cardiology, Columbia University, New York, New York 10032, USA
J Card Fail 15:108-15. 2009..Here, we review the principles of a "responder analysis.".. - Cardiology patient page. Cardiac resynchronization therapy: a better and longer life for patients with advanced heart failureSrinivas Iyengar
Division of Cardiovascular Medicine, Ohio State University, Columbus, OH 43210-1252, USA
Circulation 112:e236-7. 2005 - Cardiac resynchronization treatment of heart failureAyesha Hasan
Division of Cardiovascular Medicine, The Ohio State University College of Medicine, Columbus, Ohio 43210 1252, USA
Annu Rev Med 58:63-74. 2007..With the exponential rise in implants, new issues have emerged, such as optimal device programming, identifying appropriate candidates, and accounting for cases without clinical benefit from CRT... - Diuretic resistance in heart failureSrinivas Iyengar
The Ohio State University, 473 West 12th Avenue, Rm 110P DHLRI, Columbus, OH 43210 1252, USA
Curr Heart Fail Rep 3:41-5. 2006..The methods for overcoming this resistance are varied and require a focused approach with emphasis on relieving the congestive symptoms related to HF while attempting to preserve renal function and minimize any untoward systemic effects... - Neutral endopeptidase inhibitors and endothelin antagonistsSrinivas Iyengar
Division of Cardiology, Columbia University Medical Center, New York, NY 10032, USA
Cardiol Clin 26:41-8, vi. 2008..The reasons for these shortcomings are varied and require analysis of the design of the studies as well as the intrinsic functions of these agents... - Nonpharmacologic options for the management of heart failureRobin J Trupp
The Ohio State University, Heart and Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210 1252, USA
Curr Cardiol Rep 5:243-6. 2003..A variety of nonpharmacologic approaches compliment drug therapy of heart failure, and many have been shown to improve patient quality of life and functional capacity, while reducing morbidity and mortality... - Device therapy in advanced heart failure: what to put in and what to turn off: remote telemonitoring and implantable hemodynamic devices for advanced heart failure monitoring in the ambulatory setting and the evolving role of cardiac resynchronization theSakima A Smith
Division of Cardiovascular Medicine, The Ohio State University Medical Center, Davis Heart and Lung Research Institute, Columbus, OH 43210, USA
Congest Heart Fail 17:220-6. 2011..We also explore the growth of cardiac resynchronization therapy and how it has evolved into another tool in our armamentarium for hemodynamic monitoring... - Switching to evidence-based once-daily beta-blockers for improved adherence to medication across the continuum of post-myocardial infarction left ventricular dysfunction and heart failureWilliam T Abraham
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University, Columbus, OH 43210 1252, USA
Congest Heart Fail 14:272-80. 2008..Algorithms are provided for switching patients with heart failure or post-MI LVD from another beta-blocker to carvedilol CR... - Epidemiology of sudden cardiac death in patients with heart failureMahmoud Houmsse
Division of Cardiovascular Medicine, Department of Cardiovascular Medicine, Davis Heart and Lung Research Institute, The Ohio State University Medical Center, Suite 200, 473 West 12th Avenue, Columbus, OH 43210, USA
Heart Fail Clin 7:147-55, vii. 2011..This article discusses the incidence, prediction, and prevention of SCD in CHF due to ischemic and nonischemic cardiomyopathy... - In-hospital treatment of obstructive sleep apnea during decompensation of heart failureRami N Khayat
Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Department of Internal Medicine, Ohio State University, 201 DHLRI, 473 West 12th Ave, Columbus, OH 43210, USA
Chest 136:991-7. 2009..We evaluated the impact of immediate inpatient diagnosis and treatment of OSA in hospitalized patients with acutely decompensated heart failure (ADHF) on in-hospital cardiac outcomes... - Higher expectations for management of heart failure: current recommendationsWilliam T Abraham
Division of Cardiovascular Medicine, University of Kentucky Medical Center, Lexington, USA
J Am Board Fam Pract 15:39-49. 2002..Management of heart failure has thus entered a new era of more effective pharmacotherapy, often delivered within the primary care setting... - Ultrafiltration for volume control in decompensated heart failureGarrie J Haas
The Ohio State University Medical Center, Columbus, OH, USA
Heart Fail Clin 4:519-34. 2008..This approach, however, will require further investigation with specific emphasis on safety and costs... - Management strategies for stage-D patients with acute heart failureDavid Feldman
Department of Physiology and Cell Biology, Ohio State University, Columbus, Ohio, USA
Clin Cardiol 31:297-301. 2008..Newer surgical options such as surgical ventricular restoration may be considered in select patients... - OptiVol fluid status monitoring with an implantable cardiac device: a heart failure management systemLaura M Yamokoski
Heart Failure Program, The Ohio State University, OSU Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, 473 W 12th Ave Suite 105, Columbus, OH 43210, USA
Expert Rev Med Devices 4:775-80. 2007..9% sensitivity. Intrathoracic impedance monitoring is not intended to replace careful frequent clinical evaluation of the heart failure patient, but instead aims to complement traditional heart failure management practices... - Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patientWilliam T Abraham
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA
Rev Cardiovasc Med 4:S30-7. 2003..Given these findings, cardiac resynchronization therapy should be routinely considered in eligible NYHA Class III and IV heart failure patients with ventricular dyssynchrony... - Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular riskWilliam T Abraham
Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, Ohio, USA
Rev Cardiovasc Med 4:S30-6. 2003..Results from 1 recent study of the beta-blocker, carvedilol, have shown further that these benefits extend to high-risk patients with either diabetes or hypertension... - Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patientsWilliam T Abraham
The Ohio State University Heart Center, Division of Cardiovascular Medicine, Columbus, Ohio 43210 1252, USA
J Am Coll Cardiol 47:1615-21. 2006..The purpose of this study was to examine the renal effects of a V2 receptor arginine vasopressin (AVP) antagonist in heart failure... - Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunctionGregg C Fonarow
Rev Cardiovasc Med 4:S54-9. 2003 - Relationship between heart failure treatment and development of worsening renal function among hospitalized patientsJaved Butler
Vanderbilt University, Nashville, Tenn, USA
Am Heart J 147:331-8. 2004..Whether treatment for HF contributes to WRF is unknown. In this study, we sought to assess whether acute treatment for patients who were hospitalized with HF contributes to WRF... - Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and designGregg C Fonarow
Department of Medicine, UCLA Medical Center, Los Angeles, Calif, USA
Am Heart J 148:43-51. 2004..The ultimate aim of this program is to improve the standard of HF care in the hospital and outpatient settings and increase the use of evidence-based therapeutic strategies to save lives... - Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failureDaniel A Lewis
College of Pharmacy, University of Kentucky Chandler Medical Center, Lexington, USA
Am J Health Syst Pharm 60:S16-20. 2003..Total cost of therapy was lower in the nesiritide group as compared to those patients treated with milrinone... - Cardiac resynchronization therapy improves heart rate variability in patients with symptomatic heart failurePhilip B Adamson
Department of Internal Medicine, Cardiovascular Disease Section, University of Oklahoma Health Sciences Center, PO Box 26901, 920 SL Young Boulevard, WP3120, Oklahoma City, Okla 73104, USA
Circulation 108:266-9. 2003..The present study examined whether an improvement in ventricular performance from resynchronization therapy changes the autonomic control of heart rate... - Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rateGuido Boerrigter
Cardiorenal Research Laboratory, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
J Card Fail 14:539-46. 2008..We hypothesized that CRT would improve glomerular filtration rate as estimated by the abbreviated Modification of Diet in Renal Disease equation (eGFR)... - Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD TrialJames B Young
Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
JAMA 289:2685-94. 2003.... - Does quality of life evidence assist in the selection of patients for resynchronization therapy?Peter A McCullough
Department of Basic Science, Cardiology Section, University of Missouri Kansas City School of Medicine, Truman Medical Center, Kansas City, MO, USA
Card Electrophysiol Rev 7:71-6. 2003..In conclusion, assessment of quality of life before device implantation is necessary in order to select those individuals who are most likely to benefit from cardiac resynchronization therapy... - B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational StudyPeter A McCullough
University of California, San Diego Veteran s Affairs Medical Center, San Diego, CA, USA
Am J Kidney Dis 41:571-9. 2003..However, relationships between BNP, renal function, and heart failure as an emergency diagnosis are unknown... - Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failureAlan S Maisel
University of California, San Diego, Veterans Affairs Medical Center, San Diego 92161, USA
N Engl J Med 347:161-7. 2002..B-type natriuretic peptide is released from the cardiac ventricles in response to increased wall tension... - BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapyStephen S Gottlieb
University of Maryland School of Medicine and the D V A Medical Center, Baltimore, MD, USA
Circulation 105:1348-53. 2002..Adenosine may adversely affect renal function via its effects on renal arterioles and tubuloglomerular feedback, but effects of adenosine blockade in humans receiving furosemide and ACE inhibitors is unknown... - Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization devicePhilip B Adamson
Department of Medicine, Cardiovascular Disease and Physiology, University of Oklahoma Health Sciences Center, 920 SL Young Blvd, WP3120, Oklahoma City, OK 73104, USA
Circulation 110:2389-94. 2004..Long-term continuous HRV can be measured from an implantable device, but the clinical value of these measurements is unknown... - Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registryJoseph A Franciosa
Mount Sinai School of Medicine and Weill Medical College, Cornell University, New York, NY, USA
Am Heart J 148:718-26. 2004..beta-Blockers reduce morbidity and mortality rates in heart failure (HF) clinical trials, but it is unknown whether these findings persist in the community setting... - Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) studyCecilia Linde
Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
Congest Heart Fail 14:66-74. 2008..1% of patients. Compared with previous randomized cardiac resynchronization therapy trials, REVERSE patients are on better pharmacologic treatment, are younger, and have a narrower QRS width despite similar LV dysfunction... - Reducing events in patients with chronic heart failure (REDUCEhf ) study design: continuous hemodynamic monitoring with an implantable defibrillatorPhilip B Adamson
The Heart Failure Institute at Oklahoma Heart Hospital, Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma USA
Clin Cardiol 30:567-75. 2007..Combining a pressure sensing system with ICD therapy represents the first attempt to provide continuous hemodynamic monitoring using a device previously designed exclusively for SCD protection... - Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failureAngel R Leon
Carlyle Fraser Heart Center Division of Cardiology, Emory University, Atlanta, Georgia, USA
J Am Coll Cardiol 46:2298-304. 2005..The InSync III study evaluated sequential cardiac resynchronization therapy (CRT) in patients with moderate-to-severe heart failure and prolonged QRS... - Chronic cardiac resynchronization therapy and reverse ventricular remodeling in a model of nonischemic cardiomyopathyYoshinori Nishijima
Department of Veterinary Biosciences, United States
Life Sci 81:1152-9. 2007..The beneficial effects of CRT may be attributable, in part, to improved LV myocyte function... - Congestion in acute heart failure syndromes: importance of early recognition and treatmentLeonardo De Luca
Laboratory of Interventional Cardiology, Division of Cardiology, European Hospital, Rome, Italy
Rev Cardiovasc Med 7:69-74. 2006..It is plausible that early identification of hemodynamic congestion, before the clinical manifestations are present, could reduce the need for hospital admission and readmission... - Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVCecilia Linde
Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
Am Heart J 151:288-94. 2006..The effects of CRT on HF outcomes in patients with asymptomatic left ventricular dysfunction (ALVD) or mild HF remain to be determined...